Table 5.

Treatment-Emergent Ocular and Nonocular AEs of the Study Eye and the Fellow Eye Over 12 Months by Preferred Term

AEs, Preferred Term	Adolescent Patients*
	A	B	C
Ocular AEs
Study eye	Ocular discomfort†	Conjunctival hemorrhage†	Dry eye†
	Conjunctival hemorrhage†	Visual impairment	Conjunctival hemorrhage†
	Eye pain†		Scratch†
	Ocular hyperemia
	Eye swelling
	Vision blurred
	Conjunctival hyperemia
Fellow eye	Vision blurred	Visual impairment	—
	Lacrimation increased†
Nonocular AEs	Headache†	Epistaxis	Toxoplasmosis
	Pyrexia	Abdominal pain lower	Nasopharyngitis
	Dizziness
	Weight increased
	Tendonitis
	Vertigo

^*No AEs were reported in adolescent Patients D and E.

^†At least one episode was suspected to be related to ocular injection.